Growth Metrics

Acadia Pharmaceuticals (ACAD) Cash from Financing Activities (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Cash from Financing Activities data on record, last reported at $22.7 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1051.14% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $49.9 million, up 628.75%, while the annual FY2025 figure was $49.9 million, 628.75% up from the prior year.
  • Cash from Financing Activities reached $22.7 million in Q4 2025 per ACAD's latest filing, up from $9.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $22.7 million in Q4 2025 and bottomed at $268000.0 in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $5.4 million, with a median of $3.7 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: surged 4342.86% in 2023, then plummeted 97.9% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $4.4 million in 2021, then crashed by 63.02% to $1.6 million in 2022, then surged by 236.68% to $5.4 million in 2023, then tumbled by 63.77% to $2.0 million in 2024, then soared by 1051.14% to $22.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $22.7 million in Q4 2025, $9.4 million in Q3 2025, and $16.0 million in Q2 2025.